{
  "doc_id": "3d59775f50324ae00d246f5f64bfb5a1131186bd0c34a98ac2deb0cb041b7d0d",
  "chunk_entities": [
    {
      "chunk_id": "0da26c5a1cde90e72e6e8bb39853aa34",
      "entities": [
        {
          "entity_type": "Effect",
          "entity_name": "inflammatory response",
          "context": "mount rapid inflammatory response"
        },
        {
          "entity_type": "Compound",
          "entity_name": "pathogen-associated molecular patterns",
          "context": "via pathogen-associated molecular patterns (PAMPs)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PAMPs",
          "context": "via pathogen-associated molecular patterns (PAMPs)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "danger-associated molecular patterns",
          "context": "endogenous danger-associated molecular patterns (DAMPs)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "DAMPs",
          "context": "endogenous danger-associated molecular patterns (DAMPs)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cytokines",
          "context": "produce and release cytokines"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Pro-inflammatory",
          "context": "Pro-inflammatory cytokines"
        },
        {
          "entity_type": "Compound",
          "entity_name": "IL-1\u03b2",
          "context": "e.g., IL-1\u03b2"
        },
        {
          "entity_type": "Compound",
          "entity_name": "tumor necrosis factor-alpha",
          "context": "tumor necrosis factor-alpha"
        },
        {
          "entity_type": "Compound",
          "entity_name": "TNF-\u03b1",
          "context": "TNF-\u03b1"
        },
        {
          "entity_type": "Effect",
          "entity_name": "anti-inflammatory",
          "context": "anti-inflammatory cytokines"
        },
        {
          "entity_type": "Compound",
          "entity_name": "IL-10",
          "context": "e.g., IL-10"
        },
        {
          "entity_type": "Disease",
          "entity_name": "infection",
          "context": "site of injury or infection"
        },
        {
          "entity_type": "Disease",
          "entity_name": "prolonged inflammation",
          "context": "prolonged inflammation"
        },
        {
          "entity_type": "Disease",
          "entity_name": "chronic diseases",
          "context": "several chronic diseases"
        },
        {
          "entity_type": "Disease",
          "entity_name": "psychiatric pathologies",
          "context": "including psychiatric pathologies"
        }
      ]
    },
    {
      "chunk_id": "89b6c459b5e76058ccb8d49a65704745",
      "entities": [
        {
          "entity_type": "Disease",
          "entity_name": "psychiatric conditions",
          "context": "immune system derangements in psychiatric conditions"
        },
        {
          "entity_type": "Disease",
          "entity_name": "mental illness",
          "context": "pathophysiology of mental illness"
        },
        {
          "entity_type": "Effect",
          "entity_name": "therapeutic strategy",
          "context": "potential therapeutic strategy"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inflammatory changes",
          "context": "inflammatory changes have been seen"
        },
        {
          "entity_type": "Disease",
          "entity_name": "neuropsychiatric conditions",
          "context": "multiple neuropsychiatric conditions"
        },
        {
          "entity_type": "Disease",
          "entity_name": "autism spectrum disorder",
          "context": "such as autism spectrum disorder"
        },
        {
          "entity_type": "Disease",
          "entity_name": "bipolar disorder",
          "context": "bipolar disorder"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Alzheimer's disease",
          "context": "Alzheimer's disease"
        },
        {
          "entity_type": "Disease",
          "entity_name": "schizophrenia",
          "context": "and schizophrenia"
        },
        {
          "entity_type": "Disease",
          "entity_name": "substance use disorders",
          "context": "in substance use disorders"
        },
        {
          "entity_type": "Disease",
          "entity_name": "psychiatric conditions",
          "context": "than in the psychiatric conditions"
        }
      ]
    },
    {
      "chunk_id": "9b838ec4721a185bad10b4aaf82b5b2e",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "glutamatergic signaling",
          "context": "affect glutamatergic signaling"
        },
        {
          "entity_type": "Disease",
          "entity_name": "drug addiction",
          "context": "in drug addiction"
        },
        {
          "entity_type": "Disease",
          "entity_name": "relapse",
          "context": "and relapse"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Inflammation",
          "context": "peripheral inflammation"
        },
        {
          "entity_type": "Disease",
          "entity_name": "major depressive disorder",
          "context": "patients with major depressive disorder"
        },
        {
          "entity_type": "Compound",
          "entity_name": "glutamatergic projection neurons",
          "context": "connectivity of the glutamatergic projection neurons"
        },
        {
          "entity_type": "Effect",
          "entity_name": "pro-inflammatory",
          "context": "pro-inflammatory cytokines"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cytokines",
          "context": "pro-inflammatory cytokines"
        },
        {
          "entity_type": "Compound",
          "entity_name": "glutamate transporters",
          "context": "downregulate glutamate transporters"
        },
        {
          "entity_type": "Compound",
          "entity_name": "glutamate signaling",
          "context": "homeostasis of glutamate signaling"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "animal models of addiction"
        },
        {
          "entity_type": "Compound",
          "entity_name": "glutamate transporters",
          "context": "glutamate transporters are downregulated"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "in cocaine treated animals"
        },
        {
          "entity_type": "Compound",
          "entity_name": "glutamate",
          "context": "increase in synaptic glutamate"
        },
        {
          "entity_type": "Disease",
          "entity_name": "relapse behaviors",
          "context": "contribute to relapse behaviors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "TNF-alpha cytokine",
          "context": "the TNF-alpha cytokine"
        },
        {
          "entity_type": "Disease",
          "entity_name": "drug reward",
          "context": "in both drug reward"
        },
        {
          "entity_type": "Disease",
          "entity_name": "relapse to drug seeking",
          "context": "relapse to drug seeking"
        },
        {
          "entity_type": "Disease",
          "entity_name": "inflammation",
          "context": "effects of inflammation"
        },
        {
          "entity_type": "Disease",
          "entity_name": "substance use disorders",
          "context": "persistence of substance use disorders"
        }
      ]
    },
    {
      "chunk_id": "6397d0bc98c564306d293ca9de5e4bbe",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "effects of cocaine on peripheral expression"
        },
        {
          "entity_type": "Effect",
          "entity_name": "alters cytokine expression",
          "context": "acute cocaine alters cytokine expression in serum"
        },
        {
          "entity_type": "Compound",
          "entity_name": "monocyte chemoattractant protein 1 (MCP-1)",
          "context": "decreases in serum levels of the chemokine monocyte chemoattractant protein 1 (MCP-1)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "IL-6",
          "context": "pro-inflammatory cytokines including IL-6"
        },
        {
          "entity_type": "Compound",
          "entity_name": "IL-17",
          "context": "pro-inflammatory cytokines including IL-17"
        },
        {
          "entity_type": "Compound",
          "entity_name": "TNF-\u03b1",
          "context": "pro-inflammatory cytokines including TNF-\u03b1"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "Intravenous infusion of cocaine suppressed expression"
        },
        {
          "entity_type": "Compound",
          "entity_name": "IL-6",
          "context": "suppressed expression of serum IL-6 for four hours"
        },
        {
          "entity_type": "Effect",
          "entity_name": "suppressed expression",
          "context": "cocaine suppressed expression of serum IL-6"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "actively using cocaine have a decreased IL-6 and TNF-\u03b1 pro-inflammatory response"
        },
        {
          "entity_type": "Compound",
          "entity_name": "IL-6",
          "context": "decreased IL-6 and TNF-\u03b1 pro-inflammatory response"
        },
        {
          "entity_type": "Compound",
          "entity_name": "TNF-\u03b1",
          "context": "decreased IL-6 and TNF-\u03b1 pro-inflammatory response"
        },
        {
          "entity_type": "Effect",
          "entity_name": "decreased IL-6 and TNF-\u03b1 pro-inflammatory response",
          "context": "isolated monocytes from patients who are actively using cocaine have a decreased IL-6 and TNF-\u03b1 pro-inflammatory response"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "acute infusion of cocaine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "active cocaine users express higher levels of IL-6"
        },
        {
          "entity_type": "Compound",
          "entity_name": "IL-6",
          "context": "express higher levels of IL-6"
        },
        {
          "entity_type": "Effect",
          "entity_name": "higher levels of IL-6",
          "context": "active cocaine users express higher levels of IL-6"
        },
        {
          "entity_type": "Compound",
          "entity_name": "IL-10",
          "context": "decreased levels of the anti-inflammatory cytokine IL-10"
        },
        {
          "entity_type": "Effect",
          "entity_name": "decreased levels of IL-10",
          "context": "decreased levels of the anti-inflammatory cytokine IL-10"
        },
        {
          "entity_type": "Disease",
          "entity_name": "psychostimulant use disorders",
          "context": "patients with psychostimulant use disorders exhibit increased serum expression"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increased serum expression of pro-inflammatory markers",
          "context": "exhibit increased serum expression of pro-inflammatory markers"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibited",
          "context": "immune system of drug users may be inhibited"
        },
        {
          "entity_type": "Effect",
          "entity_name": "primed to respond in a pro-inflammatory manner",
          "context": "primed to respond to certain environmental stimuli in a pro-inflammatory manner"
        },
        {
          "entity_type": "Disease",
          "entity_name": "psychostimulant use disorders",
          "context": "development or persistence of psychostimulant use disorders"
        }
      ]
    },
    {
      "chunk_id": "882049cb461271ca6e60a3b438c1fc3f",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "patients with cocaine use disorder"
        },
        {
          "entity_type": "Disease",
          "entity_name": "cocaine use disorder",
          "context": "patients with cocaine use disorder"
        },
        {
          "entity_type": "Compound",
          "entity_name": "microglial radiotracers",
          "context": "binding of microglial radiotracers"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PET tracers",
          "context": "these PET tracers"
        }
      ]
    },
    {
      "chunk_id": "14778277192a1e5c17ee72773df8b1c7",
      "entities": [
        {
          "entity_type": "Effect",
          "entity_name": "neuroinflammatory changes",
          "context": "role of neuroinflammatory changes in animal models of psychostimulant use disorder"
        },
        {
          "entity_type": "Disease",
          "entity_name": "psychostimulant use disorder",
          "context": "animal models of psychostimulant use disorder"
        },
        {
          "entity_type": "Compound",
          "entity_name": "psychostimulants",
          "context": "role of psychostimulants and activating microglia"
        },
        {
          "entity_type": "Effect",
          "entity_name": "activating microglia",
          "context": "role of psychostimulants and activating microglia"
        },
        {
          "entity_type": "Compound",
          "entity_name": "psychostimulant",
          "context": "psychostimulant activation of astrocytes and other glial cells"
        },
        {
          "entity_type": "Effect",
          "entity_name": "activation of astrocytes",
          "context": "psychostimulant activation of astrocytes and other glial cells"
        },
        {
          "entity_type": "Effect",
          "entity_name": "activation of glial cells",
          "context": "activation of astrocytes and other glial cells"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Methamphetamine",
          "context": "Methamphetamine has been repeatedly shown to induce microglial activation"
        },
        {
          "entity_type": "Effect",
          "entity_name": "microglial activation",
          "context": "induce microglial activation throughout the brain"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibition of microglial activation",
          "context": "inhibition of microglial activation via the anti-inflammatory antibiotic minocycline"
        },
        {
          "entity_type": "Effect",
          "entity_name": "anti-inflammatory",
          "context": "via the anti-inflammatory antibiotic minocycline"
        },
        {
          "entity_type": "Compound",
          "entity_name": "minocycline",
          "context": "anti-inflammatory antibiotic minocycline"
        },
        {
          "entity_type": "Compound",
          "entity_name": "phosphodiesterase inhibitor",
          "context": "via the phosphodiesterase inhibitor and antagonist of the toll-like receptor 4 (TLR-4) ibudilast"
        },
        {
          "entity_type": "Compound",
          "entity_name": "ibudilast",
          "context": "antagonist of the toll-like receptor 4 (TLR-4) ibudilast"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduce the rewarding properties",
          "context": "ibudilast reduce the rewarding properties of stimulants"
        },
        {
          "entity_type": "Compound",
          "entity_name": "stimulants",
          "context": "rewarding properties of stimulants"
        },
        {
          "entity_type": "Effect",
          "entity_name": "microglial activation",
          "context": "mechanism of microglial activation by psychostimulants"
        },
        {
          "entity_type": "Compound",
          "entity_name": "psychostimulants",
          "context": "microglial activation by psychostimulants"
        }
      ]
    },
    {
      "chunk_id": "49515793327e1cb701a04a8d3b37f688",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "cocaine in particular may bind to TLR4"
        },
        {
          "entity_type": "Compound",
          "entity_name": "TLR4",
          "context": "may bind to TLR4"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "cocaine binds the TLR4 receptor"
        },
        {
          "entity_type": "Compound",
          "entity_name": "TLR4 receptor",
          "context": "cocaine binds the TLR4 receptor"
        },
        {
          "entity_type": "Compound",
          "entity_name": "TLR4 receptor",
          "context": "signaling through the TLR4 receptor"
        },
        {
          "entity_type": "Effect",
          "entity_name": "dopamine release",
          "context": "cocaine-induced dopamine release"
        },
        {
          "entity_type": "Effect",
          "entity_name": "conditioned place preference (CPP)",
          "context": "conditioned place preference (CPP)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "self-administration of cocaine",
          "context": "self-administration of cocaine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "self-administration of cocaine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "TLR4",
          "context": "TLR4 is necessary for basal synaptic transmission"
        },
        {
          "entity_type": "Effect",
          "entity_name": "basal synaptic transmission",
          "context": "necessary for basal synaptic transmission"
        },
        {
          "entity_type": "Effect",
          "entity_name": "NMDA-dependent synaptic plasticity",
          "context": "NMDA-dependent synaptic plasticity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "NMDA",
          "context": "NMDA-dependent synaptic plasticity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "TLR4",
          "context": "TLR4 activity in the ventral tegmental area"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reinstatement of cocaine seeking",
          "context": "affects reinstatement of cocaine seeking"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "reinstatement of cocaine seeking"
        },
        {
          "entity_type": "Compound",
          "entity_name": "IL-1",
          "context": "dependent on IL-1 signaling"
        },
        {
          "entity_type": "Compound",
          "entity_name": "TLR4 antagonists",
          "context": "effects of the TLR4 antagonists"
        },
        {
          "entity_type": "Compound",
          "entity_name": "(+)-naloxone",
          "context": "TLR4 antagonists (+)-naloxone"
        },
        {
          "entity_type": "Effect",
          "entity_name": "dopamine release",
          "context": "naloxone on dopamine release"
        },
        {
          "entity_type": "Compound",
          "entity_name": "TLR4",
          "context": "role of TLR4-mediated signaling"
        },
        {
          "entity_type": "Disease",
          "entity_name": "substance use",
          "context": "models of substance use"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "neurobiology of addiction"
        }
      ]
    },
    {
      "chunk_id": "5784e2135583c154501aae6c19c7963b",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "psychostimulants",
          "context": "gut microbiome and psychostimulants"
        }
      ]
    },
    {
      "chunk_id": "b8183b390a437984cd6964154a680cae",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "sensitization to cocaine"
        },
        {
          "entity_type": "Effect",
          "entity_name": "CPP",
          "context": "altered CPP and locomotor sensitization"
        },
        {
          "entity_type": "Effect",
          "entity_name": "locomotor sensitization",
          "context": "altered CPP and locomotor sensitization to cocaine"
        },
        {
          "entity_type": "Effect",
          "entity_name": "rewarding effects",
          "context": "more sensitive to the rewarding and sensitizing effects of cocaine"
        },
        {
          "entity_type": "Effect",
          "entity_name": "sensitizing effects",
          "context": "more sensitive to the rewarding and sensitizing effects of cocaine"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "low doses",
          "context": "effects of cocaine at low doses"
        },
        {
          "entity_type": "Compound",
          "entity_name": "brain derived neurotrophic factor (BDNF)",
          "context": "increased levels of brain derived neurotrophic factor (BDNF)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "D1 dopamine receptors",
          "context": "increased levels of ... D1 and D2 dopamine receptors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "D2 dopamine receptors",
          "context": "increased levels of ... D1 and D2 dopamine receptors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "GluR2 AMPA receptors",
          "context": "increased levels of ... GluR2 AMPA receptors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "BDNF",
          "context": "affect brain expression of BDNF and dopamine receptors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine receptors",
          "context": "affect brain expression of BDNF and dopamine receptors"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addictive behaviors",
          "context": "pathophysiology of addictive behaviors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "BDNF",
          "context": "between the microbiome and BDNF and dopamine signaling"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "between the microbiome and BDNF and dopamine signaling"
        },
        {
          "entity_type": "Compound",
          "entity_name": "methamphetamine",
          "context": "injected every other day with methamphetamine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "methamphetamine",
          "context": "bacterial diversity after methamphetamine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "propionate",
          "context": "short chain fatty acid propionate"
        },
        {
          "entity_type": "Effect",
          "entity_name": "behavioral effects",
          "context": "key role in the behavioral effects of the microbiota and cocaine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "behavioral effects of the microbiota and cocaine"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "gut-immune-brain connection in addiction"
        }
      ]
    },
    {
      "chunk_id": "a18998dea7ab79566b6d06ba56f83fcf",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Opioids",
          "context": "Opioids are used as firstline treatment"
        },
        {
          "entity_type": "Disease",
          "entity_name": "acute pain",
          "context": "many types of acute and chronic pain"
        },
        {
          "entity_type": "Disease",
          "entity_name": "chronic pain",
          "context": "many types of acute and chronic pain"
        },
        {
          "entity_type": "Disease",
          "entity_name": "chronic illnesses",
          "context": "suffering from other chronic illnesses"
        },
        {
          "entity_type": "Effect",
          "entity_name": "weakened immune systems",
          "context": "with weakened immune systems"
        },
        {
          "entity_type": "Effect",
          "entity_name": "pain management",
          "context": "abundant use in pain management"
        },
        {
          "entity_type": "Compound",
          "entity_name": "opioids",
          "context": "opioids might be impairing recovery"
        },
        {
          "entity_type": "Effect",
          "entity_name": "impairing recovery",
          "context": "opioids might be impairing recovery"
        },
        {
          "entity_type": "Compound",
          "entity_name": "opioid",
          "context": "opioid abusers have worse overall health"
        },
        {
          "entity_type": "Disease",
          "entity_name": "infectious disease complications",
          "context": "susceptible to infectious disease complications"
        },
        {
          "entity_type": "Disease",
          "entity_name": "HIV infection",
          "context": "including HIV infection"
        },
        {
          "entity_type": "Compound",
          "entity_name": "opioid",
          "context": "resulting from opioid exposure"
        },
        {
          "entity_type": "Effect",
          "entity_name": "immunosuppression",
          "context": "to general immunosuppression"
        },
        {
          "entity_type": "Disease",
          "entity_name": "HIV",
          "context": "As it pertains to HIV"
        },
        {
          "entity_type": "Compound",
          "entity_name": "heroin",
          "context": "heroin users have lower levels"
        },
        {
          "entity_type": "Compound",
          "entity_name": "tripartite motif-containing 22",
          "context": "factors tripartite motif-containing 22 (TRIM22)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "TRIM22",
          "context": "tripartite motif-containing 22 (TRIM22)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "tripartite motif-containing 5a",
          "context": "tripartite motif-containing 5a (TRIM5a)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "TRIM5a",
          "context": "tripartite motif-containing 5a (TRIM5a)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3G",
          "context": "apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3G (APOBEC3G)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "APOBEC3G",
          "context": "apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3G (APOBEC3G)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "IFN-\u03b1",
          "context": "and IFN-\u03b1"
        },
        {
          "entity_type": "Effect",
          "entity_name": "decreased the ability to combat retroviral infection",
          "context": "leads to decreased the ability to combat retroviral infection"
        },
        {
          "entity_type": "Disease",
          "entity_name": "retroviral infection",
          "context": "to combat retroviral infection"
        },
        {
          "entity_type": "Compound",
          "entity_name": "morphine",
          "context": "exposed to morphine show decreased levels"
        },
        {
          "entity_type": "Effect",
          "entity_name": "decreased levels of activation",
          "context": "show decreased levels of activation"
        },
        {
          "entity_type": "Effect",
          "entity_name": "impaired chemotactic ability",
          "context": "have impaired chemotactic ability"
        }
      ]
    },
    {
      "chunk_id": "c4fa5bb69a296a26b2673ad71fba022f",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "cytokines",
          "context": "circulatory inflammatory cytokines"
        },
        {
          "entity_type": "Compound",
          "entity_name": "TNF-alpha",
          "context": "cytokines such as TNF-alpha"
        },
        {
          "entity_type": "Disease",
          "entity_name": "heroin users",
          "context": "heroin users have higher levels"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inflammatory",
          "context": "circulatory inflammatory cytokines"
        }
      ]
    },
    {
      "chunk_id": "255674f0477537424cf2d49d2953f29d",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "transforming growth factor a (TGF-\u03b1)",
          "context": "transforming growth factor a (TGF-\u03b1)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "IL-8",
          "context": "and IL-8"
        },
        {
          "entity_type": "Compound",
          "entity_name": "morphine",
          "context": "giving morphine to healthy volunteers"
        },
        {
          "entity_type": "Effect",
          "entity_name": "cytotoxic response",
          "context": "produce less cytotoxic response"
        },
        {
          "entity_type": "Compound",
          "entity_name": "mu opioid receptor selective agonist",
          "context": "a mu opioid receptor selective agonist increased release"
        },
        {
          "entity_type": "Compound",
          "entity_name": "TGF-\u03b21",
          "context": "including TGF-\u03b21"
        },
        {
          "entity_type": "Compound",
          "entity_name": "regulated on activation, normal T cell expressed and secreted (RANTES)",
          "context": "normal T cell expressed and secreted (RANTES)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "morphine",
          "context": "morphine increased MCP-1 expression"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MCP-1",
          "context": "increased MCP-1 expression"
        },
        {
          "entity_type": "Compound",
          "entity_name": "opioids",
          "context": "when opioids are administered concurrently"
        },
        {
          "entity_type": "Effect",
          "entity_name": "dampen immune cell activation",
          "context": "act to dampen immune cell activation"
        },
        {
          "entity_type": "Compound",
          "entity_name": "heroin",
          "context": "Cells from heroin abusers"
        },
        {
          "entity_type": "Disease",
          "entity_name": "heroin abuse",
          "context": "Cells from heroin abusers"
        },
        {
          "entity_type": "Effect",
          "entity_name": "pro-inflammatory cytokines",
          "context": "lower levels of pro-inflammatory cytokines"
        },
        {
          "entity_type": "Compound",
          "entity_name": "IL-1\u03b2",
          "context": "such as IL-1\u03b2"
        },
        {
          "entity_type": "Compound",
          "entity_name": "IL-6",
          "context": "IL-6"
        },
        {
          "entity_type": "Compound",
          "entity_name": "TNF-\u03b1",
          "context": "TNF-\u03b1"
        },
        {
          "entity_type": "Compound",
          "entity_name": "IFN-\u03b3",
          "context": "and IFN-\u03b3 after in vitro stimulation"
        },
        {
          "entity_type": "Compound",
          "entity_name": "lipopolysaccharide (LPS)",
          "context": "bacterial endotoxin lipopolysaccharide (LPS)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "heroin",
          "context": "chronic heroin users produced less IFN-\u03b3"
        },
        {
          "entity_type": "Compound",
          "entity_name": "IFN-\u03b3",
          "context": "produced less IFN-\u03b3 and more IL-10"
        },
        {
          "entity_type": "Compound",
          "entity_name": "IL-10",
          "context": "and more IL-10 than healthy controls"
        },
        {
          "entity_type": "Compound",
          "entity_name": "LPS",
          "context": "stimulated with LPS"
        },
        {
          "entity_type": "Compound",
          "entity_name": "morphine",
          "context": "pretreated with morphine decreased production of IFN-\u03b3"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Concanavilin A (Con-A)",
          "context": "the toxin Concanavilin A (Con-A)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "IL-10",
          "context": "produced less IL-10 but more IL-12"
        },
        {
          "entity_type": "Compound",
          "entity_name": "IL-12",
          "context": "but more IL-12 in response to LPS"
        },
        {
          "entity_type": "Compound",
          "entity_name": "LPS",
          "context": "in response to LPS after morphine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "morphine",
          "context": "after morphine compared to LPS alone"
        },
        {
          "entity_type": "Compound",
          "entity_name": "LPS",
          "context": "compared to LPS alone"
        }
      ]
    },
    {
      "chunk_id": "c81e71a21d7723bd252bb70e64cf3226",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "opioids",
          "context": "immunosuppressive effects of opioids"
        },
        {
          "entity_type": "Effect",
          "entity_name": "immunosuppressive effects",
          "context": "immunosuppressive effects of opioids"
        },
        {
          "entity_type": "Disease",
          "entity_name": "chronic illness",
          "context": "risk of chronic illness"
        },
        {
          "entity_type": "Effect",
          "entity_name": "tolerance",
          "context": "including tolerance"
        },
        {
          "entity_type": "Effect",
          "entity_name": "dependence",
          "context": "including tolerance, dependence"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "and addiction"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Opioids",
          "context": "Opioids produce their rewarding effects"
        },
        {
          "entity_type": "Effect",
          "entity_name": "rewarding effects",
          "context": "produce their rewarding effects"
        },
        {
          "entity_type": "Compound",
          "entity_name": "GABA",
          "context": "inhibiting GABA neurons"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "disinhibition of dopamine neurons"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Opioids",
          "context": "Opioids also directly bind"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduce pain",
          "context": "to reduce pain"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cytokine",
          "context": "peripheral cytokine release"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cytokine",
          "context": "cytokine production"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cytokine",
          "context": "cytokine expression"
        },
        {
          "entity_type": "Effect",
          "entity_name": "analgesia",
          "context": "regulating both analgesia"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "and addiction"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cytokine",
          "context": "source of cytokine upregulation"
        },
        {
          "entity_type": "Compound",
          "entity_name": "opioid",
          "context": "after opioid exposure"
        },
        {
          "entity_type": "Effect",
          "entity_name": "modulating inflammation",
          "context": "role in modulating inflammation"
        },
        {
          "entity_type": "Compound",
          "entity_name": "glial inhibitors",
          "context": "glial inhibitors are being investigated"
        },
        {
          "entity_type": "Compound",
          "entity_name": "opioid",
          "context": "decrease opioid-related side effects"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "namely: addiction"
        },
        {
          "entity_type": "Effect",
          "entity_name": "physical dependence",
          "context": "and physical dependence"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Ibudilast",
          "context": "Ibudilast, a glial inhibitor"
        },
        {
          "entity_type": "Compound",
          "entity_name": "glial inhibitor",
          "context": "Ibudilast, a glial inhibitor"
        },
        {
          "entity_type": "Compound",
          "entity_name": "TNF-\u03b1",
          "context": "decrease TNF-\u03b1 release"
        },
        {
          "entity_type": "Compound",
          "entity_name": "morphine",
          "context": "subjective morphine withdrawal"
        },
        {
          "entity_type": "Effect",
          "entity_name": "morphine withdrawal",
          "context": "attenuated subjective morphine withdrawal"
        },
        {
          "entity_type": "Compound",
          "entity_name": "oxycodone",
          "context": "low-dose oxycodone"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "low-dose",
          "context": "motivation for low-dose oxycodone"
        },
        {
          "entity_type": "Compound",
          "entity_name": "heroin",
          "context": "on heroin-dependent individuals"
        }
      ]
    },
    {
      "chunk_id": "1e98b9c4ce409b227059117fd02cadfb",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "morphine",
          "context": "morphine produces an upregulation"
        },
        {
          "entity_type": "Compound",
          "entity_name": "IL-1\u03b2",
          "context": "peripheral IL-1\u03b2 acute or chronic administration"
        },
        {
          "entity_type": "Effect",
          "entity_name": "upregulation",
          "context": "produces an upregulation of peripheral IL-1\u03b2"
        },
        {
          "entity_type": "Compound",
          "entity_name": "IL-6",
          "context": "IL-6 after chronic administration"
        },
        {
          "entity_type": "Compound",
          "entity_name": "IL-17A",
          "context": "IL-17A after chronic administration"
        },
        {
          "entity_type": "Compound",
          "entity_name": "IL-10",
          "context": "IL-10 after acute administration"
        },
        {
          "entity_type": "Compound",
          "entity_name": "TNF-\u03b1",
          "context": "TNF-\u03b1, IL-2, and IFN-\u03b3"
        },
        {
          "entity_type": "Compound",
          "entity_name": "IL-2",
          "context": "IL-2, and IFN-\u03b3 after acute administration"
        },
        {
          "entity_type": "Compound",
          "entity_name": "IFN-\u03b3",
          "context": "IFN-\u03b3 after acute administration"
        },
        {
          "entity_type": "Effect",
          "entity_name": "decreased release",
          "context": "observed decreased IL-2 release"
        },
        {
          "entity_type": "Compound",
          "entity_name": "IL-2",
          "context": "decreased IL-2 release from peripheral immune cells"
        },
        {
          "entity_type": "Compound",
          "entity_name": "morphine",
          "context": "after acute and chronic morphine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "opioids",
          "context": "opioids impair immune response"
        },
        {
          "entity_type": "Effect",
          "entity_name": "impair immune response",
          "context": "opioids impair immune response to infection or injury"
        },
        {
          "entity_type": "Disease",
          "entity_name": "infection",
          "context": "immune response to infection or injury"
        },
        {
          "entity_type": "Disease",
          "entity_name": "injury",
          "context": "infection or injury in rodent models"
        },
        {
          "entity_type": "Compound",
          "entity_name": "morphine",
          "context": "injected with morphine and infected"
        },
        {
          "entity_type": "Disease",
          "entity_name": "pneumonia",
          "context": "infected with pneumonia"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Candida",
          "context": "Candida (Szabo et al., 1993)"
        },
        {
          "entity_type": "Disease",
          "entity_name": "caecal ligation",
          "context": "injured by caecal ligation"
        }
      ]
    },
    {
      "chunk_id": "63453d30fb5b094ddb97b7a47c71b3f5",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "TNF-alpha",
          "context": "TNF-alpha is not as clear."
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibition",
          "context": "inhibition of TNF-alpha"
        },
        {
          "entity_type": "Compound",
          "entity_name": "TNF-alpha",
          "context": "inhibition of TNF-alpha"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduced",
          "context": "reduced or reversed morphine tolerance"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reversed",
          "context": "reduced or reversed morphine tolerance"
        },
        {
          "entity_type": "Compound",
          "entity_name": "morphine",
          "context": "morphine tolerance"
        },
        {
          "entity_type": "Effect",
          "entity_name": "tolerance",
          "context": "morphine tolerance"
        },
        {
          "entity_type": "Effect",
          "entity_name": "knockout",
          "context": "knockout of TNF-alpha"
        },
        {
          "entity_type": "Compound",
          "entity_name": "TNF-alpha",
          "context": "knockout of TNF-alpha"
        },
        {
          "entity_type": "Effect",
          "entity_name": "nociceptive responses",
          "context": "acute nociceptive responses"
        },
        {
          "entity_type": "Effect",
          "entity_name": "tolerance",
          "context": "nociceptive responses or tolerance"
        }
      ]
    },
    {
      "chunk_id": "cbf0c320530382ff6d995ca8d7d7a74e",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Morphine",
          "context": "Morphine and other opioids are known to bind opioid receptors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "opioids",
          "context": "Morphine and other opioids are known to bind opioid receptors"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reward",
          "context": "to produce reward"
        },
        {
          "entity_type": "Effect",
          "entity_name": "dependence",
          "context": "to produce reward, dependence"
        },
        {
          "entity_type": "Effect",
          "entity_name": "analgesia",
          "context": "and analgesia"
        },
        {
          "entity_type": "Effect",
          "entity_name": "disrupt inflammatory signaling",
          "context": "in order to disrupt inflammatory signaling"
        },
        {
          "entity_type": "Compound",
          "entity_name": "(+)-isomers of opioids",
          "context": "that (+)- and (-)-isomers of opioids bind TLR4"
        },
        {
          "entity_type": "Compound",
          "entity_name": "(-)-isomers of opioids",
          "context": "that (+)- and (-)-isomers of opioids bind TLR4"
        },
        {
          "entity_type": "Compound",
          "entity_name": "TLR4",
          "context": "isomers of opioids bind TLR4 and opioid receptors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "opioid receptors",
          "context": "isomers of opioids bind TLR4 and opioid receptors"
        },
        {
          "entity_type": "Disease",
          "entity_name": "inflammation",
          "context": "role of inflammation in morphine-induced behaviors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "(+)-Naloxone",
          "context": "(+)-Naloxone and (+)-naltrexone are putative antagonists"
        },
        {
          "entity_type": "Compound",
          "entity_name": "(+)-naltrexone",
          "context": "(+)-Naloxone and (+)-naltrexone are putative antagonists"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reverse morphine tolerance",
          "context": "shown to reverse morphine tolerance"
        },
        {
          "entity_type": "Effect",
          "entity_name": "enhance morphine's analgesic effect",
          "context": "and enhance morphine's analgesic effect"
        },
        {
          "entity_type": "Effect",
          "entity_name": "impaired the development of morphine CPP",
          "context": "disruption of TLR4 signaling impaired the development of morphine CPP"
        },
        {
          "entity_type": "Compound",
          "entity_name": "remifentanil",
          "context": "self-administration of remifentanil"
        },
        {
          "entity_type": "Effect",
          "entity_name": "self-administration of remifentanil",
          "context": "self-administration of remifentanil"
        },
        {
          "entity_type": "Compound",
          "entity_name": "heroin",
          "context": "incubation of heroin craving"
        },
        {
          "entity_type": "Effect",
          "entity_name": "incubation of heroin craving",
          "context": "incubation of heroin craving"
        },
        {
          "entity_type": "Effect",
          "entity_name": "enhanced microglial activation",
          "context": "show enhanced microglial activation in response to morphine"
        },
        {
          "entity_type": "Effect",
          "entity_name": "normal morphine tolerance",
          "context": "as well as normal morphine tolerance"
        },
        {
          "entity_type": "Effect",
          "entity_name": "dependence",
          "context": "and dependence"
        },
        {
          "entity_type": "Effect",
          "entity_name": "opioid reward",
          "context": "do not affect opioid reward"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "clinically relevant doses",
          "context": "at clinically relevant doses"
        }
      ]
    },
    {
      "chunk_id": "b41784bfa586f03918dd9a0e64208ded",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "opioids",
          "context": "opioids influence inflammation"
        },
        {
          "entity_type": "Compound",
          "entity_name": "pro-inflammatory cytokines",
          "context": "upregulation of pro-inflammatory cytokines"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inflammation",
          "context": "opioids influence inflammation"
        },
        {
          "entity_type": "Effect",
          "entity_name": "immune reactivity",
          "context": "immune reactivity in a variety of ways"
        },
        {
          "entity_type": "Effect",
          "entity_name": "opioid-related behaviors",
          "context": "affect opioid-related behaviors"
        },
        {
          "entity_type": "Effect",
          "entity_name": "upregulation of pro-inflammatory cytokines",
          "context": "upregulation of pro-inflammatory cytokines after short- or prolonged opioid exposure"
        },
        {
          "entity_type": "Effect",
          "entity_name": "enhanced activation of microglia",
          "context": "enhanced activation of microglia"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduction in the immune response",
          "context": "reduction in the immune response to pathogens"
        },
        {
          "entity_type": "Effect",
          "entity_name": "disruption of intestinal permeability",
          "context": "disruption of intestinal permeability"
        },
        {
          "entity_type": "Disease",
          "entity_name": "pathogens",
          "context": "immune response to pathogens"
        },
        {
          "entity_type": "Disease",
          "entity_name": "systemic bacterial spread",
          "context": "leading to systemic bacterial spread"
        },
        {
          "entity_type": "Effect",
          "entity_name": "tolerance",
          "context": "negative consequences of opioid use, such as tolerance"
        },
        {
          "entity_type": "Effect",
          "entity_name": "dependence",
          "context": "dependence (Bland et al., 2009; Hutchinson et al., 2009)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reward",
          "context": "and reward (Hutchinson et al., 2008b; Zhang et al., 2012)"
        }
      ]
    },
    {
      "chunk_id": "8fafdd27117c8bfb4e029d656c6740fc",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "psychostimulants",
          "context": "psychostimulants and opioids have robust and complex effects"
        },
        {
          "entity_type": "Compound",
          "entity_name": "opioids",
          "context": "psychostimulants and opioids have robust and complex effects"
        },
        {
          "entity_type": "Disease",
          "entity_name": "substance use disorders",
          "context": "persistence of substance use disorders"
        }
      ]
    },
    {
      "chunk_id": "50a15928e4c629e7223e960636fec5d6",
      "entities": [
        {
          "entity_type": "Disease",
          "entity_name": "substance use disorders",
          "context": "animal models of substance use disorders"
        },
        {
          "entity_type": "Compound",
          "entity_name": "drugs of abuse",
          "context": "how drugs of abuse affect specific synaptic functions"
        },
        {
          "entity_type": "Effect",
          "entity_name": "anti-inflammatory",
          "context": "not as simples as provs. anti-inflammatory"
        },
        {
          "entity_type": "Effect",
          "entity_name": "pro-inflammatory",
          "context": "pro-inflammatory IL-1\\beta drives"
        },
        {
          "entity_type": "Compound",
          "entity_name": "IL-1\\beta",
          "context": "pro-inflammatory IL-1\\beta drives increased behavioral response"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "behavioral response to cocaine and opioids"
        },
        {
          "entity_type": "Compound",
          "entity_name": "opioids",
          "context": "cocaine and opioids"
        },
        {
          "entity_type": "Effect",
          "entity_name": "pro-inflammatory",
          "context": "pro-inflammatory TNF-\\alpha inhibits response"
        },
        {
          "entity_type": "Compound",
          "entity_name": "TNF-\\alpha",
          "context": "pro-inflammatory TNF-\\alpha inhibits response to cocaine"
        },
        {
          "entity_type": "Effect",
          "entity_name": "anti-inflammatory",
          "context": "anti-inflammatory IL-10 reduces behavioral response"
        },
        {
          "entity_type": "Compound",
          "entity_name": "IL-10",
          "context": "anti-inflammatory IL-10 reduces behavioral response for opioids"
        },
        {
          "entity_type": "Compound",
          "entity_name": "opioids",
          "context": "reduces behavioral response for opioids"
        },
        {
          "entity_type": "Compound",
          "entity_name": "G-CSF",
          "context": "while G-CSF, which is primarily anti-inflammatory"
        },
        {
          "entity_type": "Effect",
          "entity_name": "anti-inflammatory",
          "context": "which is primarily anti-inflammatory"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "enhances behavioral responses to cocaine"
        }
      ]
    },
    {
      "chunk_id": "6eb1597a76fc4e744572859cc5af4916",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "\\alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid",
          "context": "AMPA\\alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3G",
          "context": "APO-BEC3GApolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3G"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Brain-derived neurotrophic factor",
          "context": "BDNFBrain-derived neurotrophic factor"
        },
        {
          "entity_type": "Compound",
          "entity_name": "C-C chemokine receptor type 2",
          "context": "CCR2 C-Cchemokine receptor type 2"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Concanavalin A",
          "context": "Con-AConcanavalin A"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Danger-associated molecular pattern",
          "context": "DAMPDanger-associated molecular pattern"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Eosinophil chemotactic protein",
          "context": "ECPEosinophil chemotactic protein"
        }
      ]
    },
    {
      "chunk_id": "9a5610ec78fd8c1d9138d6420d7d32a0",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Extracellular-regulated kinase",
          "context": "ERKExtracellular-regulated kinase"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Granulocyte colony-stimulating factor",
          "context": "G-CSFGranulocyte colony-stimulating factor"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Growth-related oncogene",
          "context": "GRO/KCGrowth-related oncogene/keratinocyte chemoattractant"
        },
        {
          "entity_type": "Compound",
          "entity_name": "keratinocyte chemoattractant",
          "context": "GRO/KCGrowth-related oncogene/keratinocyte chemoattractant"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Hepatic encephalopathy",
          "context": "HEHepatic encephalopathy"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Interferon alpha",
          "context": "IFN-alphaInterferon alpha"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Interferon gamma",
          "context": "IFN-gammaInterferon gamma"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Interleukin-10",
          "context": "IL-10Interleukin-10"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Interleukin-12",
          "context": "IL-12Interleukin-12"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Interleukin-17",
          "context": "IL-17Interleukin-17"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Interleukin-1 beta",
          "context": "IL-1betaInterleukin-1 beta"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Interleukin-2",
          "context": "IL-2Interleukin-2"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Interleukin-6",
          "context": "IL-6Inter-leukin-6"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Interleukin-8",
          "context": "IL-8Interleukin-8"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Lipopolysaccharide",
          "context": "LPSLipopolysaccharide"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Monocyte chemoattractant protein 1",
          "context": "MCP-1Monocyte chemoattractant protein 1"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Monocyte chemoattractant protein 5",
          "context": "MCP-5Monocyte chemoattractant protein 5"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Major depressive disorder",
          "context": "MDDMajor depressive disorder"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Monokine induced by gamma interferon",
          "context": "MIG-1Monokine induced by gamma interferon"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Macrophage inflammatory protein 1 alpha",
          "context": "MIP-1alphaMacrophage inflammatory protein 1 alpha"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Macrophage inflammatory protein 1 beta",
          "context": "MIP-1betaMacrophage inflammatory protein 1 beta"
        },
        {
          "entity_type": "Compound",
          "entity_name": "N-methyl-D-aspartate",
          "context": "NMDAN-methyl-D-aspartate"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Pathogen-associated molecular pattern",
          "context": "PAMPPathogen-associated molecular pattern"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Pattern recognition receptor",
          "context": "PRRPattern recognition receptor"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Regulated on activation, normal T cell expressed and secreted",
          "context": "RANTESRegulated on activation, normal T cell expressed and secreted"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Stromal cell-derived factor 1",
          "context": "SDF-1Stro-mal cell-derived factor 1"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Thymus and activation-regulated chemokine",
          "context": "TARCThymus and activation-regulated chemokine"
        }
      ]
    },
    {
      "chunk_id": "5da9e4b2b0775a17660037dc59532827",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Tumor Necrosis Factor",
          "context": "role of TNF in the regulation"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Tumor Necrosis Factor alpha",
          "context": "Microglial TNF\\alpha suppresses cocaine-induced plasticity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "suppresses cocaine-induced plasticity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "plasticity",
          "context": "cocaine-induced plasticity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "behavioral sensitization",
          "context": "behavioral sensitization"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "brain dopamine cell numbers"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "human cocaine users"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Naloxone",
          "context": "Naloxone-precipitated morphine withdrawal behavior"
        },
        {
          "entity_type": "Compound",
          "entity_name": "morphine",
          "context": "morphine withdrawal behavior"
        },
        {
          "entity_type": "Effect",
          "entity_name": "withdrawal behavior",
          "context": "morphine withdrawal behavior"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Interleukin-1 beta",
          "context": "brain IL-1\\beta expression"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Morphine",
          "context": "Morphine-induced alterations of immune status"
        },
        {
          "entity_type": "Effect",
          "entity_name": "antagonism",
          "context": "antagonism by naltrexone"
        },
        {
          "entity_type": "Compound",
          "entity_name": "naltrexone",
          "context": "antagonism by naltrexone"
        },
        {
          "entity_type": "Compound",
          "entity_name": "opiate alkaloid",
          "context": "an opiate alkaloid-selective receptor"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibition",
          "context": "mediating inhibition of cyto-kine-induced activation"
        },
        {
          "entity_type": "Effect",
          "entity_name": "activation",
          "context": "cyto-kine-induced activation and chemotaxis"
        },
        {
          "entity_type": "Effect",
          "entity_name": "chemotaxis",
          "context": "activation and chemotaxis"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "Effects of cocaine on the hypothalamic\u2013pituitary\u2013adrenal axis"
        },
        {
          "entity_type": "Compound",
          "entity_name": "morphine",
          "context": "Loss of morphine-induced analgesia"
        },
        {
          "entity_type": "Effect",
          "entity_name": "analgesia",
          "context": "morphine-induced analgesia"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reward effect",
          "context": "reward effect and withdrawal symptoms"
        },
        {
          "entity_type": "Effect",
          "entity_name": "withdrawal symptoms",
          "context": "withdrawal symptoms in mice"
        },
        {
          "entity_type": "Compound",
          "entity_name": "mu-opioid receptor",
          "context": "lacking the \\mu-opioid-receptor gene"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Buprenorphine",
          "context": "Buprenorphine maintenance versus placebo"
        },
        {
          "entity_type": "Compound",
          "entity_name": "placebo",
          "context": "versus placebo or methadone maintenance"
        },
        {
          "entity_type": "Compound",
          "entity_name": "methadone",
          "context": "or methadone maintenance for opioid dependence"
        },
        {
          "entity_type": "Disease",
          "entity_name": "opioid dependence",
          "context": "maintenance for opioid dependence"
        },
        {
          "entity_type": "Compound",
          "entity_name": "morphine",
          "context": "retain morphine-induced tolerance"
        },
        {
          "entity_type": "Effect",
          "entity_name": "tolerance",
          "context": "morphine-induced tolerance"
        },
        {
          "entity_type": "Effect",
          "entity_name": "hyperalgesia",
          "context": "hyperalgesia, and physical dependence"
        },
        {
          "entity_type": "Effect",
          "entity_name": "physical dependence",
          "context": "and physical dependence"
        },
        {
          "entity_type": "Compound",
          "entity_name": "alcohol",
          "context": "component of alcohol abuse"
        },
        {
          "entity_type": "Disease",
          "entity_name": "alcohol abuse",
          "context": "component of alcohol abuse"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cytokines",
          "context": "Evaluation of plasma cytokines"
        },
        {
          "entity_type": "Disease",
          "entity_name": "cocaine use disorders",
          "context": "patients with cocaine use disorders"
        },
        {
          "entity_type": "Compound",
          "entity_name": "transforming growth factor alpha",
          "context": "identifies transforming growth factor alpha (TG\\alpha)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Heroin",
          "context": "Heroin use is associated with suppressed"
        },
        {
          "entity_type": "Effect",
          "entity_name": "suppressed pro-inflammatory cytokine response",
          "context": "suppressed pro-inflammatory cytokine response after LPS exposure"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Lipopolysaccharide",
          "context": "after LPS exposure in HIV-infected individuals"
        },
        {
          "entity_type": "Disease",
          "entity_name": "HIV-infected",
          "context": "in HIV-infected individuals"
        },
        {
          "entity_type": "Disease",
          "entity_name": "depression",
          "context": "promoting depression"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Opioid",
          "context": "Opioid exacerbation of gram-positive sepsis"
        },
        {
          "entity_type": "Disease",
          "entity_name": "sepsis",
          "context": "gram-positive sepsis"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Interleukin-17A",
          "context": "rescued by IL-17A neutralization"
        },
        {
          "entity_type": "Compound",
          "entity_name": "opioids",
          "context": "Extended-release opioids in the management"
        },
        {
          "entity_type": "Disease",
          "entity_name": "cancer pain",
          "context": "management of cancer pain"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Morphine",
          "context": "Morphine reciprocally regulates IL-10"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Interleukin-10",
          "context": "regulates IL-10 and IL-12 production"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Interleukin-12",
          "context": "and IL-12 production by monocyte-derived"
        },
        {
          "entity_type": "Effect",
          "entity_name": "T cell activation",
          "context": "enhances T cell activation"
        },
        {
          "entity_type": "Compound",
          "entity_name": "ibudilast",
          "context": "Effects of ibudilast on the subjective"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reinforcing effects",
          "context": "reinforcing, and analgesic effects of oxycodone"
        },
        {
          "entity_type": "Effect",
          "entity_name": "analgesic effects",
          "context": "analgesic effects of oxycodone"
        },
        {
          "entity_type": "Compound",
          "entity_name": "oxycodone",
          "context": "effects of oxycodone in recently detoxified"
        },
        {
          "entity_type": "Disease",
          "entity_name": "opioid dependence",
          "context": "adults with opioid dependence"
        },
        {
          "entity_type": "Disease",
          "entity_name": "drug abuse",
          "context": "glial cells in drug abuse"
        }
      ]
    },
    {
      "chunk_id": "0cafc8e7d1e89c2b3bd888ea148f213e",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "chemokines",
          "context": "names of chemokines"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "by cocaine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "opioids",
          "context": "or opioids"
        }
      ]
    },
    {
      "chunk_id": "1b502720da0b13ea5d1620757b800733",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "MCP-1",
          "context": "MCP-1 (monocyte chemoattractant protein 1)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "monocyte chemoattractant protein 1",
          "context": "(monocyte chemoattractant protein 1)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CCL2",
          "context": "CCL2"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MIP-1\\alpha",
          "context": "MIP-1\\alpha (macrophage inflammatory protein-1 alpha)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "macrophage inflammatory protein-1 alpha",
          "context": "(macrophage inflammatory protein-1 alpha)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CCL3",
          "context": "CCL3"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MIP-1\\beta",
          "context": "MIP-1\\beta (macrophage inflammatory protein-1 beta)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "macrophage inflammatory protein-1 beta",
          "context": "(macrophage inflammatory protein-1 beta)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CCL4",
          "context": "CCL4"
        },
        {
          "entity_type": "Compound",
          "entity_name": "RANTES",
          "context": "RANTES (regulated on activation, normal T cell expressed and secreted)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "regulated on activation, normal T cell expressed and secreted",
          "context": "(regulated on activation, normal T cell expressed and secreted)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CCL5",
          "context": "CCL5"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MCP-2",
          "context": "MCP-2 (monocyte chemoattractant protein 2)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "monocyte chemoattractant protein 2",
          "context": "(monocyte chemoattractant protein 2)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CCL8",
          "context": "CCL8"
        },
        {
          "entity_type": "Compound",
          "entity_name": "ECP",
          "context": "ECP (eosinophil chemotactic protein)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "eosinophil chemotactic protein",
          "context": "(eosinophil chemotactic protein)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CCL11",
          "context": "CCL11"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MCP-5",
          "context": "MCP-5 (monocyte chemoattractant protein 5)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "monocyte chemoattractant protein 5",
          "context": "(monocyte chemoattractant protein 5)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CCL12",
          "context": "CCL12"
        },
        {
          "entity_type": "Compound",
          "entity_name": "TARC",
          "context": "TARC (thymus and activation-regulated chemokine)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "thymus and activation-regulated chemokine",
          "context": "(thymus and activation-regulated chemokine)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CCL17",
          "context": "CCL17"
        },
        {
          "entity_type": "Compound",
          "entity_name": "TECK",
          "context": "TECK (thymus-expressed chemokine)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "thymus-expressed chemokine",
          "context": "(thymus-expressed chemokine)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CCL25",
          "context": "CCL25"
        },
        {
          "entity_type": "Compound",
          "entity_name": "GRO/KC",
          "context": "GRO/KC (growth-related oncogene/keratinocyte chemoattractant)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "growth-related oncogene/keratinocyte chemoattractant",
          "context": "(growth-related oncogene/keratinocyte chemoattractant)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CXCL1",
          "context": "CXCL1"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MIG",
          "context": "MIG (monokine induced by gamma interferon)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "monokine induced by gamma interferon",
          "context": "(monokine induced by gamma interferon)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CXCL9",
          "context": "CXCL9"
        },
        {
          "entity_type": "Compound",
          "entity_name": "SDF-1",
          "context": "SDF-1 (stromal cell-derived factor 1)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "stromal cell-derived factor 1",
          "context": "(stromal cell-derived factor 1)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CXCL12",
          "context": "CXCL12"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Fractalkine",
          "context": "Fractalkine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CX3CL1",
          "context": "CX3CL1"
        }
      ]
    },
    {
      "chunk_id": "573654bbc1a372f38a1e51a55c6e5fc7",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "CCL2",
          "context": "CCL2, chemokine (C-C motif) ligand 2"
        },
        {
          "entity_type": "Compound",
          "entity_name": "chemokine (C-C motif) ligand 2",
          "context": "CCL2, chemokine (C-C motif) ligand 2"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CCL3",
          "context": "CCL3, chemokine (C-C motif) ligand 3"
        },
        {
          "entity_type": "Compound",
          "entity_name": "chemokine (C-C motif) ligand 3",
          "context": "CCL3, chemokine (C-C motif) ligand 3"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CCL4",
          "context": "CCL4, chemokine (C-C motif) ligand 4"
        },
        {
          "entity_type": "Compound",
          "entity_name": "chemokine (C-C motif) ligand 4",
          "context": "CCL4, chemokine (C-C motif) ligand 4"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CCL5",
          "context": "CCL5, chemokine (C-C motif) ligand 5"
        },
        {
          "entity_type": "Compound",
          "entity_name": "chemokine (C-C motif) ligand 5",
          "context": "CCL5, chemokine (C-C motif) ligand 5"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CCL8",
          "context": "CCL8, chemokine (C-C motif) ligand 8"
        },
        {
          "entity_type": "Compound",
          "entity_name": "chemokine (C-C motif) ligand 8",
          "context": "CCL8, chemokine (C-C motif) ligand 8"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CCL11",
          "context": "CCL11, chemokine (C-C motif) ligand 11"
        },
        {
          "entity_type": "Compound",
          "entity_name": "chemokine (C-C motif) ligand 11",
          "context": "CCL11, chemokine (C-C motif) ligand 11"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CCL12",
          "context": "CCL12, chemokine (C-C motif) ligand 12"
        },
        {
          "entity_type": "Compound",
          "entity_name": "chemokine (C-C motif) ligand 12",
          "context": "CCL12, chemokine (C-C motif) ligand 12"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CCL17",
          "context": "CCL17, chemokine (C-C motif) ligand 17"
        },
        {
          "entity_type": "Compound",
          "entity_name": "chemokine (C-C motif) ligand 17",
          "context": "CCL17, chemokine (C-C motif) ligand 17"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CCL25",
          "context": "CCL25, chemokine (C-C motif) ligand 25"
        },
        {
          "entity_type": "Compound",
          "entity_name": "chemokine (C-C motif) ligand 25",
          "context": "CCL25, chemokine (C-C motif) ligand 25"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CXCL1",
          "context": "CXCL1, chemokine (C-X-C motif) ligand 1"
        },
        {
          "entity_type": "Compound",
          "entity_name": "chemokine (C-X-C motif) ligand 1",
          "context": "CXCL1, chemokine (C-X-C motif) ligand 1"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CXCL9",
          "context": "CXCL9, chemokine (C-X-C motif) ligand 9"
        },
        {
          "entity_type": "Compound",
          "entity_name": "chemokine (C-X-C motif) ligand 9",
          "context": "CXCL9, chemokine (C-X-C motif) ligand 9"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CXCL12",
          "context": "CXCL12, chemokine (C-X-C motif) ligand 12"
        },
        {
          "entity_type": "Compound",
          "entity_name": "chemokine (C-X-C motif) ligand 12",
          "context": "CXCL12, chemokine (C-X-C motif) ligand 12"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CX3CL1",
          "context": "CX3CL1, chemokine (C-X3-C motif) ligand 1"
        },
        {
          "entity_type": "Compound",
          "entity_name": "chemokine (C-X3-C motif) ligand 1",
          "context": "CX3CL1, chemokine (C-X3-C motif) ligand 1"
        }
      ]
    }
  ],
  "total_entities": 477,
  "extraction_date": "2026-02-01T08:54:02.395285+00:00"
}